Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Affimed Ord Shs
(NQ:
AFMD
)
7.100
+0.010 (+0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Affimed Ord Shs
< Previous
1
2
3
Next >
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
August 03, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
July 31, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
June 22, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
June 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
June 03, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
May 25, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
May 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
May 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
May 22, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
May 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
May 11, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
April 26, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
April 17, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
April 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
April 06, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
March 29, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports 2022 Financial Results and Operational Progress
March 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
March 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
March 14, 2023
From
Affimed N.V.
Via
GlobeNewswire
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
March 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
February 22, 2023
From
Affimed N.V.
Via
GlobeNewswire
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
February 21, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
February 08, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
January 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
December 22, 2022
From
Affimed N.V.
Via
GlobeNewswire
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
December 12, 2022
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
December 10, 2022
From
Affimed N.V.
Via
GlobeNewswire
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
December 10, 2022
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
December 01, 2022
From
Affimed N.V.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.